Accepting
gifts or travel arrangements from drugmakers is against the law in
India, but enforcement is inconsistent. Abbott Laboratories has
instructed its sales representatives in India not to give gifts to
doctors, who are prohibited by local law from accepting them, a practice
that has been used as a bargaining chip by companies wanting a piece of
the country's burgeoning healthcare market. Full Article
Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Valsartan and Hydrochlorothiazide Tablets USP, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg and 320mg/25mg (ANDA 202519). The product is ready for launch.
Valsartan and Hydrochlorothiazide Tablets USP, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg and 320mg/25mg is generic equivalent to Novartis Pharmaceuticals Corp.’s Diovan HCT Tablets 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg and 320mg/25mg respectively. The product is indicated for the treatment of hypertension, to lower blood pressure and falls under the cardiovascular (CVS) therapeutic category. The market size of the product is approximately US$1.7 Billion for the twelve months ending September 2012.
Aurobindo now has a total of 181 ANDA approvals (156 Final approvals including 2 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA.
Venus Remedies has launched its first OTC product ‘Ezenus’, a stress reliever. Ezenus is a unique medical nutrition product which is absolutely safe, zero calorie, non-addictive, herbal candy, with clinically proven anti-stress activity. With the launch of Ezenus, the company is entering into the OTC segment for the first time. The company is hopeful that this novel research Ezenus will acquire 5% of the product 100 million dollar direct market of stress segment in India, other than lifestyle disorders, within 3 years of its launch.
Ezenus is world’s first anti stress product launched in easy to use candy form even suitable for diabetic patients. It is highly safe in acute stress management such as exam stress in children and in chronic stress like in alcoholic and smoking population, without change in life style by continuous detoxification and strong antioxidant activity.
Ezenus reduces more than 60% stress within 30 days without change in life style and significantly improves the quality of life in terms of physical, social, emotional and functional well- being. This breakthrough innovative product is suitable for all ages with safety established upto 10 times advised dose.
--
CA Mihir Desai
--
You received this message because you are subscribed to the Google Groups "LONGTERMINVESTORSRESEARCH" group.
To unsubscribe from this group and stop receiving emails from it, send an email to longterminvestorsr...@googlegroups.com.
For more options, visit https://groups.google.com/groups/opt_out.
(Reuters) - Drugmaker Cadila Healthcare Ltd(CADI.NS) received regulatory approval to market a new diabetes drug in India that it developed and is aiming for more than $1 billion in sales globally, the company said on Wednesday.
Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India, the company's chairman, Pankaj Patel, said.
"We expect this to be a blockbuster drug, which means over $1 billion sales a year" when the drug is sold globally, he told a news conference. For now the company is hoping for Lipaglyn sales of 1 billion rupees in India over three years, he said.
Cadila took about eight years to develop the molecule and conducted clinical trials on more than 1,000 patients in India, Patel said.
The company plans to launch two other new chemical entities in the next seven years and has eight drugs in various stages of clinical development, he added.
Traders on Tuesday had driven up the company's shares by 5.2 percent in anticipation the company would make a bigger announcement than the drug approval on Wednesday such as a stake buy and drove the shares down 4.2 percent in afternoon trading. (Reporting by Kaustubh Kulkarni; Writing by Ranjit Gangadharan; Editing by Matt Driskill)